INTRODUCTION
NSCLC, chronic pulmonary disease, cancer, Lung cancer, lung cancer, immune‐related adverse events
CANCER, LUNG CANCER, LUNG CANCER, CHRONIC PULMONARY DISEASE, NSCLC
Lung cancer is the primary cause of cancer‐related mortality worldwide.However, immunotherapy also causes a broad spectrum of immune‐related adverse events (irAEs) that can affect multiple organ system.CIP may lead to severe clinical outcomes, which tend to be overlooked by clinicians due to the overall low incidence of irAEs. The standard treatment for ≥Grade 3 CIP remains high doses of corticosteroid or combined with immunosuppressive agents if necessary.Therefore, it is crucial to prevent and monitor the occurrence of CIP in advanced NSCLC patients receiving ICIs. Since CIP occurs in a relatively small population, it is essential to identify patients with risk factors for CIP. Previous studies demonstrated that a history of chronic pulmonary disease, prior thoracic radiotherapy, and abnormality in some peripheral‐blood parameters are associated with occurrences of CIP.However, researches are scarce regarding establishing a CIP risk prediction model, which might be helpful in practice for clinicians to rule out a small portion of patients at significant risk of developing CIP. Recently, nomogram has been widely used in oncology to predict the efficacy and safety of cancer therapy as it spares clinicians from complicated calculations used in traditional risk prediction models. Multiple studies on lung cancer patients receiving immunotherapy have employed nomograms to predict overall survival probabilities based on clinicopathologic features.